

TOPIC: **Furthering Global Biopharma:
Opportunities for Development with East Asia**

- SESSIONS:*
1. Opportunities for Collaboration with Japan's Public Sector and Academia
 - **Mr. Hideki Mitani**, Senior Advisor to Director General, Institute of Industrial Science, Senior Advisor to Dean, The Institute of Medical Science, The University of Tokyo
 - **Mr. Hiroyuki Kawabata**, Director, Health and Welfare Department, JETRO New York
 - **Mr. Kenjiro Watanabe**, Director, Business Development, JETRO New York
 2. Designing and Conducting Clinical Trials in Asia
 - **Dr. James M. Pusey MD, MBA**, SVP Clinical Operations, Medpace
 3. New Drug Discovery and Development in Korea: A Case Study
 - **Dr. Saeho Chong**, Sr VP Business Development, Enzychem Lifesciences USA Corporation
 - Moderator, **Ms. Kimberly Ha**, Senior Consultant of FTI Consulting
 4. Opportunities and Deal Making with Asian Biopharma
 - **Ms. Kathryn Gregory**, Executive Director, Licensing & Business Development, Purdue Pharma L.P.
 - **Dr. Daniel G. Chain**, President and CEO, CereSpir Inc.
 - **Dr. Shoshana Shendelman**, Managing Director, Clearpoint Strategy Group LLC
 - **Tony Chen**, CEO, PrimeVax Immuno-Oncology, Inc.
 - Moderator, **Ms. Kimberly Ha**, Senior Consultant of FTI Consulting

With Asian economies and markets expanding, global pharmaceutical companies are looking to forge deeper business and research relationships in Asia, and Asian pharma companies are looking to promote themselves and increase market-share abroad. South Korea is investing heavily in technology and promoting pharmaceutical sector companies as they look to build a presence in the biosimilars market, forecast by Citigroup to be worth \$18 billion by 2025. Japan's pharmaceutical market is the second largest in the world, representing a little less than 10% of the global pharma market, with 2013 sales estimated at \$115.

We are happy to be co-hosting this program with the New York Health Forum where experts will discuss opportunities in Asia for biopharmaceutical companies with a focus on collaboration, development, clinical trials, and deal making.